Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
Guselkumab demonstrated significant and clinically meaningful responses in paediatric patients with moderate-to-severe plaque psoriasis, and all co-primary and major secondary endpoints were met. Safety outcomes for guselkumab in paediatric patients were similar to placebo and consistent with the established profile in adults, with no new safety signals identified. These findings support the use of guselkumab to treat paediatric patients with moderate-to-severe plaque psoriasis.
Authors
- Herta Crauwels (ORCID: https://orcid.org/0000-0002-4516-8830)
- Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
- Erzsébet Szakos
- Marieke M.B. Seyger (ORCID: https://orcid.org/0000-0003-0516-8294)
- Andrzej Kaszuba
- Dagmar Wilsmann‐Theis (ORCID: https://orcid.org/0000-0002-5594-7192)
- Shu Li (ORCID: https://orcid.org/0000-0002-6073-6285)
- Guangliang Jiang (ORCID: https://orcid.org/0000-0001-7359-4733)
- Vikash Sinha (ORCID: https://orcid.org/0000-0002-6573-3323)
- Cynthia Marie Carver DeKlotz (ORCID: https://orcid.org/0000-0002-6410-8710)
- Vimal H Prajapati
- Bart van Hartingsveldt
- Meg Jett
Institutions
- Northwestern University (US)
- Janssen (Belgium) (BE)
- Radboud University Nijmegen (NL)
- University of Calgary (CA)
- University of Miskolc (HU)
- University Hospital Bonn (DE)
- Radboud University Medical Center (NL)
- SKiN Health (CA)
- Calgary Laboratory Services (CA)
- Springhouse (US)
- Medical University of Lodz (PL)
- Probity Medical Research (CA)
- Skin Wellness Center (US)
- Janssen (United States) (US)
- Janssen (Netherlands) (NL)
- Center for Rheumatology (US)
- Dermatology Research Center (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1093/bjd/ljae502
- Citations
- 4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.96
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Celgene
- Janssen Scientific Affairs
- LEO Pharma
- Janssen Research and Development